The in vitro activity of LY303366, a new echinocandin derivative, was evaluated with 191 yeast isolates by a broth microdilution method. The MICs at which 50% of the isolates were inhibited were 0.125 g/ml for Candida albicans and C. tropicalis, 0.25 g/ml for C. krusei, C. kefyr, and C. glabrata, and 2.0 g/ml for C. parapsilosis.
obtain stock solutions with a concentration of 1,280 g/ml, and all three solutions were stored at Ϫ70°C.
The MICs of all antifungal agents were determined in accordance with the National Committee for Clinical Laboratory Standards M27-T standards by a microdilution method (8) . Briefly, RPMI 1640 with L-glutamine and without sodium bicarbonate (Sigma Chemical Co., St. Louis, Mo.), buffered at pH 7 with 0.165 M morpholinepropanesulfonic acid (MOPS), was used. The final drug concentrations ranged from 16 to 0.03 g/ml for LY303366 and amphotericin B and from 64 to 0.125 g/ml for fluconazole and were obtained by 10 twofold serial dilutions. The yeast suspensions were spectrophotometrically prepared and diluted to obtain a final inoculum of 0.5 ϫ 10 3 to 2.5 ϫ 10 3 CFU/ml. All organisms were tested in duplicate in each run of the experiments.
The microtiter plates were incubated at 35°C, and MICs were assessed at 24 and 48 h visually by three separate investigators. Fluconazole plates were read after agitation as previously described (2) . The MICs of LY303366 and amphotericin B were defined as the lowest concentrations at which no growth was observed, and for fluconazole, the MIC was defined as the lowest concentration at which a prominent decrease in turbidity was observed.
LY303366 had the lowest MICs at which 50% of the isolates were inhibited (MIC 50 s) and MIC 90 s against the C. albicans, C. krusei, C. kefyr, and C. tropicalis strains tested (Table 1 ). For C. glabrata isolates, the MIC 50 of LY303366 was 0.25 g/ml, whereas it was 0.5 g/ml for amphotericin B and 4.0 g/ml for fluconazole. There were three isolates of C. parapsilosis, and MICs of LY303366 for these isolates (2.0 g/ml for two isolates and 4.0 g/ml for one isolate) as well as for C. parapsilosis ATCC 90018 and ATCC 22019 (2.0 g/ml) were higher than those for other Candida strains. The MICs obtained for the ATCC strains are shown in Table 2 . For C. albicans ATCC 64550, the MIC range of fluconazole was 16 to 32 g/ml, the MIC range of amphotericin B was 0.5 to 1.0 g/ml, and the MIC range of LY303366 was 0.06 to 0.125 g/ml. For C. albicans ATCC 64552 fluconazole had an MIC range of 0.125 to 0.25 g/ml, amphotericin B had an MIC range of 2.0 to 4.0 g/ml, and LY303366 had an MIC range of 0.125 to 0.25 g/ml in all the sets of experiments. LY303366 had no in vitro activity against the T. beigelii strains tested; for all three T. beigelii isolates, the MICs of LY303366 were Ͼ16, with significant turbidity in all wells. The 48-h MIC readings were comparable to the 24-h MIC readings for all the antifungal agents and strains tested (data not shown); the changes in MICs were within twofold for all strains.
The results of this study show that LY303366 possesses potent in vitro activity against a variety of Candida species, including C. albicans, C. krusei, C. kefyr, C. tropicalis, and C. glabrata. The most exciting observation was the good in vitro activity of this compound against C. krusei, which is resistant to fluconazole, and C. glabrata, for which fluconazole has higher MICs than for other non-C. albicans Candida strains. None of our C. albicans isolates were resistant to fluconazole; however, Pfaller et al. reported that LY303366 inhibited all isolates with elevated fluconazole MICs (Ն128 g/ml) at a concentration of Յ0.5 g/ml when tested in RPMI (9) . This excellent in vitro activity against azole-resistant Candida strains may have important implications for the management of difficult-to-treat Candida infections.
The MICs for the three clinical isolates of C. parapsilosis were relatively high. Because of the very small number tested, this could be interpreted as a strain-specific result. However, LY303366 was reported to possess the least activity against C. parapsilosis of any antifungal agent tested by other investigators as well (7, 9) . On the other hand, LY303366 had no activity against three T. beigelii strains. This finding requires further investigation.
In summary, LY303366 is a promising antifungal drug which exhibits good in vitro activity against not only Candida species known to be usually susceptible to fluconazole, such as C. albicans, but also putatively fluconazole-resistant C. krusei and C. glabrata. Nevertheless, the true activity of this compound against various fungal pathogens will depend on its pharmacokinetic and pharmacodynamic properties and the toxicity profile in humans.
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